SARS-CoV-2-related Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease: A Case Report and Literature Review

Intern Med. 2022 Apr 15;61(8):1253-1258. doi: 10.2169/internalmedicine.8709-21. Epub 2022 Feb 8.

Abstract

We herein report a case of myelin oligodendrocyte glycoprotein (MOG) antibody-associated disease after severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. A 24-year-old woman developed unilateral optic neuritis 3 weeks after contracting coronavirus disease 2019 (COVID-19), followed by intracranial demyelinating lesions and myelitis. Since serum anti-MOG antibody was positive, we diagnosed MOG antibody-associated disease. Immunotherapy with steroids resulted in the rapid improvement of neurological symptoms. This is a suggestive case, as there are no reports of MOG antibody-associated disease with multiple neurological lesions occurring after COVID-19. The response to immunotherapy was favorable. This case suggests that it is important to measure anti-MOG antibodies in patients who develop inflammatory neurological disease after COVID-19.

Keywords: COVID-19; MOG antibody-associated disease; SARS-CoV-2; demyelinating autoimmune disease; myelitis; optic neuritis.

Publication types

  • Case Reports
  • Review

MeSH terms

  • Autoantibodies
  • COVID-19* / complications
  • Female
  • Humans
  • Myelin-Oligodendrocyte Glycoprotein
  • Optic Neuritis*
  • SARS-CoV-2
  • Young Adult

Substances

  • Autoantibodies
  • Myelin-Oligodendrocyte Glycoprotein